Risk of Nonmelanoma Skin Cancers and Parkinson’s Disease—Meta-Analysis and Systematic Review
Abstract
:Simple Summary
Abstract
1. Introduction
2. Results
2.1. Characteristics of the Studies Included in the Analysis
2.2. Risk of NMSCs in PD patients
2.3. Risk of NMSC Subtypes in PD Patients
2.3.1. BCC
2.3.2. SCC
2.4. Sex-Related Risk of NMSC in PD Patients
2.5. Risk of NMSCs in PD Patients Depending on the Order of Diagnosis
2.6. Risk of NMSCs in PD Patients Depending on the Type of Research (Prospective or Retrospective)
2.7. Evaluation for Publication Bias
3. Discussion
4. Materials and Methods
4.1. Search Strategy
4.2. Eligibility Criteria
4.3. Data Extraction
4.4. Statistical Analysis
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Ascherio, A.; Schwarzschild, M.A. The epidemiology of Parkinson’s disease: Risk factors and prevention. Lancet Neurol. 2016, 15, 1257–1272. [Google Scholar] [CrossRef]
- Kalia, L.V.; Lang, A.E. Parkinson’s disease. Lancet 2015, 386, 896–912. [Google Scholar] [CrossRef]
- Lin, P.-Y.; Chang, S.-N.; Hsiao, T.-H.; Huang, B.-T.; Lin, C.-H.; Yang, P.-C. Association Between Parkinson Disease and Risk of Cancer in Taiwan. JAMA Oncol. 2015, 1, 633–640. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bajaj, A.; Driver, J.A.; Schernhammer, E.S. Parkinson’s disease and cancer risk: A systematic review and meta-analysis. Cancer Causes Control. 2010, 21, 697–707. [Google Scholar] [CrossRef]
- Fois, A.F.; Wotton, C.J.; Yeates, D.; Turner, M.R.; Goldacre, M.J. Cancer in patients with motor neuron disease, multiple sclerosis and Parkinson’s disease: Record linkage studies. J. Neurol. Neurosurg. Psychiatry 2010, 81, 215–221. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sun, L.-M.; Liang, J.-A.; Chang, S.-N.; Sung, F.-C.; Muo, C.-H.; Kao, C.-H. Analysis of Parkinson’s Disease and Subsequent Cancer Risk in Taiwan: A Nationwide Population-Based Cohort Study. Neuroepidemiology 2011, 37, 114–119. [Google Scholar] [CrossRef] [PubMed]
- West, A.B.; Dawson, V.L.; Dawson, T.M. To die or grow: Parkinson’s disease and cancer. Trends Neurosci. 2005, 28, 348–352. [Google Scholar] [CrossRef]
- Bose, A.; Petsko, G.A.; Eliezer, D. Parkinson’s Disease and Melanoma: Co-Occurrence and Mechanisms. J. Park. Dis. 2018, 8, 385–398. [Google Scholar] [CrossRef] [Green Version]
- Ferreira, J.J.; Neutel, D.; Mestre, T.; Coelho, M.; Rosa, M.M.; Rascol, O.; Sampaio, C. Skin cancer and Parkinson’s disease. Mov. Disord. 2010, 25, 139–148. [Google Scholar] [CrossRef]
- Inzelberg, R.; Rabey, J.M.; Melamed, E.; Djaldetti, R.; Reches, A.; Badarny, S.; Hassin-Baer, S.; Cohen, O.; Trau, H.; Aharon-Peretz, J.; et al. High prevalence of malignant melanoma in Israeli patients with Parkinson’s disease. J. Neural Transm. 2011, 118, 1199–1207. [Google Scholar] [CrossRef]
- Lerman, S.; Amichai, B.; Weinstein, G.; Shalev, V.; Chodick, G. Parkinson’s Disease, Melanoma, and Keratinocyte Carcinoma: A Population-Based Study. Neuroepidemiology 2018, 50, 168–173. [Google Scholar] [CrossRef] [PubMed]
- Dalvin, L.A.; Damento, G.M.; Yawn, B.P.; Abbott, B.A.; Hodge, D.O.; Pulido, J.S. Parkinson Disease and Melanoma. Mayo Clin. Proc. 2017, 92, 1070–1079. [Google Scholar] [CrossRef] [PubMed]
- Van Der Pols, J.C. Epidemiology of Basal Cell and Squamous Cell Carcinoma of the Skin. In Skin Cancer—A World-Wide Perspective; Springer: Berlin/Heidelberg, Germany, 2011; pp. 3–12. [Google Scholar] [CrossRef]
- Samarasinghe, V.; Madan, V. Nonmelanoma skin cancer. J. Cutan. Aesthetic Surg. 2012, 5, 3–10. [Google Scholar] [CrossRef] [PubMed]
- Apalla, Z.; Lallas, A.; Sotiriou, E.; Lazaridou, E.; Ioannides, D. Epidemiological trends in skin cancer. Dermatol. Pr. Concept. 2017, 7, 1–6. [Google Scholar] [CrossRef] [Green Version]
- Rowell, D.; Gordon, L.G.; Olsen, C.M.; Whiteman, D.C. A comparison of the direct medical costs for individuals with or without basal or squamous cell skin cancer: A study from Australia. SAGE Open Med. 2016, 4, 205031211664603. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Elbaz, A.; Peterson, B.J.; Yang, P.; Van Gerpen, J.A.; Bower, J.H.; Maraganore, D.M.; McDonnell, S.K.; Ahlskog, J.E.; Rocca, W.A. Nonfatal Cancer Preceding Parkinson’s Disease: A Case-Control Study. Epidemiology 2002, 13, 157–164. [Google Scholar] [CrossRef]
- Elbaz, A.; Peterson, B.J.; Bower, J.H.; Yang, P.; Maraganore, D.M.; McDonnell, S.K.; Ahlskog, J.E.; Rocca, W.A. Risk of cancer after the diagnosis of Parkinson’s disease: A historical cohort study. Mov. Disord. 2005, 20, 719–725. [Google Scholar] [CrossRef]
- Olsen, J.H.; Friis, S.; Frederiksen, K. Malignant Melanoma and Other Types of Cancer Preceding Parkinson Disease. Epidemiology 2006, 17, 582–587. [Google Scholar] [CrossRef]
- Powers, K.M.; Smith-Weller, T.; Franklin, G.M.; Longstreth, W.; Swanson, P.D.; Checkoway, H. Diabetes, smoking, and other medical conditions in relation to Parkinson’s disease risk. Park. Relat. Disord. 2006, 12, 185–189. [Google Scholar] [CrossRef]
- Olsen, J.H.; Tangerud, K.; Wermuth, L.; Frederiksen, K.; Friis, S. Treatment with levodopa and risk for malignant melanoma. Mov. Disord. 2007, 22, 1252–1257. [Google Scholar] [CrossRef]
- Ferreira, J.J.; Silva, J.N.M.; Freire, R.; Pignatelli, J.; Guedes, L.C.; Feijó, A.; Rosa, M.M.; Coelho, M.; Costa, J.; Noronha, A.; et al. Skin cancers and precancerous lesions in Parkinson’s disease patients. Mov. Disord. 2007, 22, 1471–1475. [Google Scholar] [CrossRef] [PubMed]
- Rugbjerg, K.; Friis, S.; Lassen, C.F.; Ritz, B.; Olsen, J.H. Malignant melanoma, breast cancer and other cancers in patients with Parkinson’s disease. Int. J. Cancer 2012, 131, 1904–1911. [Google Scholar] [CrossRef] [PubMed]
- Wirdefeldt, K.; Weibull, C.E.; Chen, H.; Kamel, F.; Lundholm, C.; Fang, F.; Ye, W. Parkinson’s disease and cancer: A register-based family study. Am. J. Epidemiol. 2014, 179, 85–94. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tacik, P.; Curry, S.; Fujioka, S.; Strongosky, A.; Uitti, R.J.; Van Gerpen, J.A.; Diehl, N.N.; Heckman, M.G.; Wszolek, Z.K. Cancer in Parkinson’s disease. Park. Relat. Disord. 2016, 31, 28–33. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shalaby, S.Y.; Louis, E.D. Increased Odds of Melanoma: Parkinson’s Disease, Essential Tremor, Dystonia versus Controls. Neuroepidemiology 2016, 46, 128–136. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ryu, H.J.; Park, J.; Choi, M.; Jung, J.; Han, K.; Kwon, D.; Kim, D.; Park, Y.-G. Parkinson’s disease and skin cancer risk: A nationwide population-based cohort study in Korea. J. Eur. Acad. Dermatol. Venereol. 2020, 34, 2775–2780. [Google Scholar] [CrossRef] [PubMed]
- Driver, J.A.; Kurth, B.-M.; Buring, J.E.; Gaziano, J.M.; Logroscino, G. Prospective case–control study of nonfatal cancer preceding the diagnosis of parkinson’s disease. Cancer Causes Control. 2007, 18, 705–711. [Google Scholar] [CrossRef]
- Gao, X.; Ning, Y. Cancer and Parkinson’s disease: The odd couple. Drugs Today 2011, 47, 215–222. [Google Scholar] [CrossRef]
- Huang, P.; Yang X-D, X.; Chen, S.-D.; Xiao, Q. The association between Parkinson’s disease and melanoma: A systematic review and meta-analysis. Transl. Neurodegener. 2015, 4, 21. [Google Scholar] [CrossRef] [Green Version]
- Liu, R.; Gao, X.; Lu, Y.; Chen, H. Meta-analysis of the relationship between Parkinson disease and melanoma. Neurology 2011, 76, 2002–2009. [Google Scholar] [CrossRef] [Green Version]
- Olsen, J.H.; Friis, S.; Frederiksen, K.; McLaughlin, J.K.; Mellemkjaer, L.; Møller, H. Atypical cancer pattern in patients with Parkinson’s disease. Br. J. Cancer 2005, 92, 201–205. [Google Scholar] [CrossRef] [PubMed]
- Jucevičiūtė, N.; Banaitytė, I.; Vaitkus, A.; Balnytė, R. Preclinical signs of Parkinson’s disease: A possible association of Parkinson’s disease with skin and hair features. Med. Hypotheses 2019, 127, 100–104. [Google Scholar] [CrossRef] [PubMed]
- Gao, X.; Simon, K.C.; Han, J.; Schwarzschild, M.A.; Ascherio, A. Genetic determinants of hair color and parkinson’s disease risk. Ann. Neurol. 2009, 65, 76–82. [Google Scholar] [CrossRef] [PubMed]
- Feller, L.; Khammissa, R.A.G.; Kramer, B.; Altini, M.; Lemmer, J. Basal cell carcinoma, squamous cell carcinoma and melanoma of the head and face. Head Face Med. 2016, 12, 11. [Google Scholar] [CrossRef] [Green Version]
- Ferrucci, L.M.; Cartmel, B.; Molinaro, A.M.; Gordon, P.B.; Leffell, D.J.; Bale, A.E.; Mayne, S.T. Host Phenotype Characteristics and MC1R in Relation to Early-Onset Basal Cell Carcinoma. J. Investig. Dermatol. 2012, 132, 1272–1279. [Google Scholar] [CrossRef] [Green Version]
- Tell-Marti, G.; Puig-Butille, J.A.; Potrony, M.; Badenas, C.; Milà, M.; Malvehy, J.; Martí, M.J.; Ezquerra, M.; Fernández-Santiago, R.; Puig, S. TheMC1Rmelanoma risk variant p.R160W is associated with Parkinson disease. Ann. Neurol. 2015, 77, 889–894. [Google Scholar] [CrossRef]
- Avci, C.B.; Kaya, I.; Ozturk, A.; Ay, N.P.O.; Sezgin, B.; Kurt, C.C.; Akyildiz, N.S.; Bozan, A.; Yaman, B.; Akalin, T.; et al. The role of EGFR overexpression on the recurrence of basal cell carcinomas with positive surgical margins. Gene 2019, 687, 35–38. [Google Scholar] [CrossRef]
- Wu, S.; Han, J.; Li, W.-Q.; Li, T.; Qureshi, A.A. Basal-Cell Carcinoma Incidence and Associated Risk Factors in US Women and Men. Am. J. Epidemiol. 2013, 178, 890–897. [Google Scholar] [CrossRef] [Green Version]
- Kenborg, L.; Lassen, C.F.; Ritz, B.; Schernhammer, E.S.; Hansen, J.; Gatto, N.M.; Olsen, J.H. Outdoor work and risk for Parkinson’s disease: A population-based case-control study. Occup. Environ. Med. 2011, 68, 273–278. [Google Scholar] [CrossRef] [Green Version]
No. | Authors | Year of Publication | Diagnosis before or after PD | Type of Research | PD-NMSCs/ PD n, (%) | OR | 95%CI | Country | Sex | PD Diagnosis | Cancer Diagnosis |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | Elbaz [17] | 2002 | Before | Retrospective | 13/196 (2.88%) | 0.79 | 0.36–1.73 | The United States | Both | Medical records | Medical records |
2 | Elbaz [18] | 2005 | After | Retrospective | 39/196 (6.63%) | 1.76 | 1.07–2.89 | The United States | Both | Medical records | Medical records |
3 | Olsen [19] | 2006 | Before | Population-based case-control study | 343/8090 (4.24%) | 1.26 | 1.11–1.43 | Dennmark | Both | Medical records | Medical records |
4 | Powers [20] | 2006 | Both | Case-control study | 39/352 (19.90%) | 1.05 | 0.61–1.82 | The United States | Men | Medical records | Self-reported questionnaire |
5 | Powers [20] | 2006 | Both | Case-control study | 1.19 | 0.53–2.71 | The United States | Women | Medical records | Self-reported questionnaire | |
6 | Olsen [21] | 2007 | After | Retrospective | 328/14088 (2.33%) | 1.21 | 1.09–1.35 | Dennmark | Both | Medical records | Medical records |
7 | Ferreira [22] | 2007 | After | Prospective | 4/150 (2.67%) | 1.97 | 0.36–10.94 | Portugal | Both | Neurologist | Dermatologist /pathology reports |
8 | Fois [5] | 2010 | Before | Retrospective | 168/4355 (3.85%) | 1 | 0.80–1.10 | England | Both | Medical records | Medical records |
9 | Fois [5] | 2010 | After | Retrospective | 17/4355 (0.39%) | 0.6 | 0.30–0.90 | England | Both | Medical records | Medical records |
10 | Inzelberg [10] | 2011 | Both (only BCC) | Prospective | 8/1395 (0.57%) | 2.39 | 0.95–6.04 | Israel | Both | Neurologist | Dermatologist/ pathology report |
11 | Sun [6] | 2011 | After | Retrospective | - | 0.88 | 0.78–0.99 | Taiwan | Both | Medical records | Medical records |
12 | Rugbjerg [23] | 2012 | Both | Retrospective | 586/20343 (25.00%) | 1.29 | 1.18–1.39 | Dennmark | Both | Medical records | Medical records |
13 | Wirdefeldt [24] | 2014 | Before (>1 year) | Retrospective | 172/11786 (1.46%) | 1.05 | 0.82–1.36 | Sweden | Both | Medical records | Medical records (clinical/pathological) |
14 | Wirdefeldt [24] | 2014 | After (>1 year) | Retrospective | 1.4 | 1.04–1.88 | Sweden | Both | Medical record | Medical records (clinical/pathological) | |
15 | Wirdefeldt [24] | 2014 | ±1 year before or after | Retrospective | 1.54 | 0.96–2.49 | Sweden | Both | Medical records | Medical records (clinical/pathological) | |
16 | Lin [3] | 2015 | After | Retrospective | - | 1.81 | 1.46–2.23 | Taiwan | Both | Medical records | Medical records histological report |
17 | Tacik [25] | 2016 | Both | Retrospective | 155/971 (11.08%) | 0.62 | 0.45–0.84 | The United States | Both | Movement disorder specialist | Medical records |
18 | Shalaby [26] | 2016 | Both | Prospective | 27/108 (9.54%) | 2.63 | 1.24–5.62 | The United States | Both | Neurologist | Dermatologist/Pathology reports |
19 | Lerman [11] | 2018 | After | Retrospective | 737/7727 (0.68%) | 3.31 | 3.06–3.57 | Israel | Both | Medical records | Pathology reports |
20 | Ryu [27] | 2020 | After (>1 year) | Retrospective | 186/70730 (0.26%) | 1.13 | 0.96–1.32 | Korea | Both | Medical records | Medical records |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Krasowska, D.; Gerkowicz, A.; Mlak, R.; Leziak, M.; Małecka-Massalska, T.; Krasowska, D. Risk of Nonmelanoma Skin Cancers and Parkinson’s Disease—Meta-Analysis and Systematic Review. Cancers 2021, 13, 587. https://doi.org/10.3390/cancers13040587
Krasowska D, Gerkowicz A, Mlak R, Leziak M, Małecka-Massalska T, Krasowska D. Risk of Nonmelanoma Skin Cancers and Parkinson’s Disease—Meta-Analysis and Systematic Review. Cancers. 2021; 13(4):587. https://doi.org/10.3390/cancers13040587
Chicago/Turabian StyleKrasowska, Danuta, Agnieszka Gerkowicz, Radosław Mlak, Milena Leziak, Teresa Małecka-Massalska, and Dorota Krasowska. 2021. "Risk of Nonmelanoma Skin Cancers and Parkinson’s Disease—Meta-Analysis and Systematic Review" Cancers 13, no. 4: 587. https://doi.org/10.3390/cancers13040587
APA StyleKrasowska, D., Gerkowicz, A., Mlak, R., Leziak, M., Małecka-Massalska, T., & Krasowska, D. (2021). Risk of Nonmelanoma Skin Cancers and Parkinson’s Disease—Meta-Analysis and Systematic Review. Cancers, 13(4), 587. https://doi.org/10.3390/cancers13040587